Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06802146 · ClinicalTrials.gov registry record · Early Phase 1
Early Intervention in High Risk CCUS
A Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance, sponsored by Lachelle D. Weeks, MD, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06802146: Recruiting Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance, sponsored by Lachelle D. Weeks, MD, PhD.
NCT06802146 is a Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance that is actively recruiting participants, run by Lachelle D. Weeks, MD, PhD. The registered enrollment target is 108 participants, below the 369-participant average among 11 other Cytopenia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06802146, a Early Phase 1 study of Cytopenia and Clonal Cytopenia of Undetermined Significance, is actively recruiting participants, sponsored by Lachelle D. Weeks, MD, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment. The names of the study drug involved in this study is: -Decitabine/cedazuridine (DEC/CED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).
Primary Outcome
FFR is defined by the proportion of eligible subjects with higher risk CCUS who enter the study and opt to participate in the early intervention as opposed to observation only cohort.
Conditions Studied
Interventions
- DRUG Inqovi
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2025-02-07 |
| Est. Completion | 2028-12-01 |
| Phase | Early Phase 1 |
What NCT06802146 shows while recruiting
NCT06802146 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 369-participant average among 11 other Cytopenia trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Cytopenia appearing as the primary indexed condition, and to 1 intervention - of which Inqovi is the first listed.
NCT06802146 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06802146 about?
NCT06802146 is a clinical study titled "Early Intervention in High Risk CCUS". This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatme...
What is the current status of trial NCT06802146?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 108 participants. The study started on 2025-02-07. Estimated completion is 2028-12-01.
What conditions does trial NCT06802146 study?
This clinical trial studies the following conditions: Cytopenia, Clonal Cytopenia of Undetermined Significance.
What interventions are being tested in trial NCT06802146?
The interventions under investigation include: Inqovi (DRUG).
Who is sponsoring clinical trial NCT06802146?
This trial is sponsored by Lachelle D. Weeks, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06802146 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06802146's enrollment target sits among peer trials
108 6th of 11 higher than 6 of 11 other Cytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of a Peripheral Blood Assay to Replace BM Evaluation in Cytopenia - a Multi-Center Observational Study
RECRUITING
-
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
RECRUITING · NA
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Danazol for Treatment of Cytopenias in Patients With Cirrhosis
RECRUITING · Phase 2
-
A Study of Emapalumab for Pediatric Aplastic Anemia
RECRUITING · Phase 2
-
A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI